- Home
- AIIO vs LAB Comparison
AIIO vs LAB Comparison
Compare AIIO & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIIO
- LAB
- Stock Information
- Founded
- AIIO N/A
- LAB 1999
- Country
- AIIO United Arab Emirates
- LAB United States
- Employees
- AIIO N/A
- LAB N/A
- Industry
- AIIO Auto Manufacturing
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- AIIO Industrials
- LAB Industrials
- Exchange
- AIIO Nasdaq
- LAB Nasdaq
- Market Cap
- AIIO 468.5M
- LAB 449.9M
- IPO Year
- AIIO N/A
- LAB 2011
- Fundamental
- Price
- AIIO $0.56
- LAB $1.23
- Analyst Decision
- AIIO
- LAB Hold
- Analyst Count
- AIIO 0
- LAB 2
- Target Price
- AIIO N/A
- LAB $1.35
- AVG Volume (30 Days)
- AIIO 5.7M
- LAB 1.5M
- Earning Date
- AIIO 05-27-2026
- LAB 11-04-2025
- Dividend Yield
- AIIO N/A
- LAB N/A
- EPS Growth
- AIIO N/A
- LAB N/A
- EPS
- AIIO N/A
- LAB N/A
- Revenue
- AIIO $5,742,000.00
- LAB $169,737,000.00
- Revenue This Year
- AIIO N/A
- LAB N/A
- Revenue Next Year
- AIIO N/A
- LAB N/A
- P/E Ratio
- AIIO N/A
- LAB N/A
- Revenue Growth
- AIIO N/A
- LAB 79.77
- 52 Week Low
- AIIO $0.30
- LAB $0.92
- 52 Week High
- AIIO $3.48
- LAB $2.25
- Technical
- Relative Strength Index (RSI)
- AIIO 35.30
- LAB 48.04
- Support Level
- AIIO $0.51
- LAB $1.16
- Resistance Level
- AIIO $0.73
- LAB $1.26
- Average True Range (ATR)
- AIIO 0.12
- LAB 0.07
- MACD
- AIIO 0.02
- LAB 0.01
- Stochastic Oscillator
- AIIO 26.84
- LAB 72.50
About AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.